COVID-19 pill developers aim to top Merck, Pfizer efforts - Reuters
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS Sept 28 (Reuters) - As Merck & Co (MRK.N) and Pfizer Inc (PFE.N) prepare to report clinical trial results for experimental COVID-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own. Enanta Pharmaceuticals (ENTA.O), Pardes Biosciences, Japan's Shionogi & Co Ltd (4507.T) and Novartis AG (NOVN.S) said they have designed antivirals that specifically target the coronavirus while aiming to avoid potential shortcomings such as the need for multiple pills per day or known safety issues. Infectious disease experts stressed that preventing COVID-19 through wide use of vaccines remains the best way to control t...